Nurtec ODT vs Maxalt MLT-ODT for Migraine
What You Need to Know Before You Apply
What is the purpose of this trial?
Rimegepant (Nurtec) is an orally administered small molecule CGRP receptor antagonist with efficacy in the acute treatment of migraine. Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT1B and 5-HT1D receptors which leads to activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal pain pathways with resultant relieve of the headache.Teh investigators hypothesize that the administration of Rimegepant ODT would provide better analgesic efficacy than Rizatriptan ODT with respect to analgesic efficacy at 60 min and 120 minutes in ED patients with acute headache.This is a prospective, randomized, double-blind superiority trial evaluating and comparing analgesic efficacy and safety of Rimegepant ODT 75 mg to Rizatriptan ODT 10 mg in adult patients presenting to the Emergency Department of Maimonides Medical Center with acute migraine headache.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications, including other migraine medications like triptans, some antidepressants, and specific antibiotics and antifungals. If you're on any of these, you may need to stop them before participating.
How does the drug Rimegepant differ from other migraine treatments?
What data supports the effectiveness of the drug Rimegepant (Nurtec ODT) for treating migraines?
Rimegepant, available as an orally disintegrating tablet, has been shown to be more effective than a placebo in relieving pain and reducing the number of migraine days in adults, both for immediate relief and long-term prevention. It is well tolerated and does not show harmful effects on the liver or heart.12346
Who Is on the Research Team?
Sergey Motov, MD
Principal Investigator
Maimonides Medical Center
Are You a Good Fit for This Trial?
This trial is for adult emergency department patients with acute migraine headaches. Specific eligibility criteria are not provided, but typically participants must have a diagnosis of migraine and be able to take oral medication.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Rimegepant ODT 75 mg or Rizatriptan ODT 10 mg in the ED, with pain levels assessed every 30 minutes for up to 120 minutes
Follow-up
Participants are contacted by telephone 24 hours after ED discharge to ascertain headache status, satisfaction with treatment, and presence of adverse events
What Are the Treatments Tested in This Trial?
Interventions
- Rimegepant
- Rizatriptan Benzoate
Rimegepant is already approved in United States, European Union, Canada, United Kingdom for the following indications:
- Acute treatment of migraine with or without aura in adults
- Preventative treatment of episodic migraine in adults
- Prophylaxis and acute treatment of migraine in adults
- Acute treatment of migraine with or without aura in adults
- Preventative treatment of episodic migraine in adults
- Prophylaxis and acute treatment of migraine in adults
Find a Clinic Near You
Who Is Running the Clinical Trial?
Antonios Likourezos
Lead Sponsor